LONDON, May 2 (Reuters) - Novo Nordisk has

seen the price of its hugely popular weight-loss drug Wegovy

fall in the United States as volumes and competition have

increased, and it expects that to continue through the year, a

senior executive said on Thursday.

Wegovy prices in the United States were "slightly down" in

the first quarter, Chief Financial Officer Karsten Munk Knudsen

said on a call with media.

The comments came after the Danish drugmaker raised its

full-year outlook due to explosive demand for the weekly

injection.